Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$12.93
+5.6%
$9.33
$4.11
$28.68
$80.65M2.85171,319 shs98,880 shs
Geron Corporation stock logo
GERN
Geron
$1.41
-5.4%
$1.44
$1.17
$5.06
$949.01M0.6911.23 million shs14.43 million shs
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$0.00
$0.00
$1.59
$1K1.535.14 million shsN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$1.03
$1.01
$0.32
$1.57
$211.41M2.151.93 million shsN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.50
-0.1%
$27.24
$18.92
$81.73
$2.98B0.654.02 million shs4.40 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
+5.55%+1.33%+53.93%+74.02%+60,095.53%
Geron Corporation stock logo
GERN
Geron
-5.37%-0.70%-8.74%-4.73%-66.75%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00%0.00%0.00%-50.00%-99.99%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.08%+6.60%-1.78%+10.83%-50.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.0285 of 5 stars
3.54.00.00.02.51.70.6
Geron Corporation stock logo
GERN
Geron
3.0497 of 5 stars
3.41.00.01.31.61.70.6
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.4884 of 5 stars
0.00.00.04.70.60.00.6
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.1187 of 5 stars
4.51.00.04.71.41.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$61.00371.77% Upside
Geron Corporation stock logo
GERN
Geron
2.78
Moderate Buy$5.06259.04% Upside
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00
N/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00
N/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.15228.88% Upside

Current Analyst Ratings Breakdown

Latest GERN, MTEM, SPPI, VKTX, and FBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
5/8/2025
Geron Corporation stock logo
GERN
Geron
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.50
4/29/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$104.00
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$95.00 ➝ $75.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
4/17/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
4/8/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$30.00
4/1/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$64.00 ➝ $61.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
Geron Corporation stock logo
GERN
Geron
$76.99M11.66N/AN/A$0.46 per share3.07
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$23.48M0.00N/AN/A$0.78 per share0.00
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$10.11M20.91N/AN/A$0.15 per share6.87
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)
Geron Corporation stock logo
GERN
Geron
-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.15N/AN/AN/AN/A-14.41%-14.02%7/23/2025 (Estimated)

Latest GERN, MTEM, SPPI, VKTX, and FBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.89-$1.37-$0.48-$1.37N/AN/A
5/7/2025Q1 2025
Geron Corporation stock logo
GERN
Geron
-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million
4/23/2025Q1 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.31-$0.41-$0.10-$0.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
5.22
5.22
Geron Corporation stock logo
GERN
Geron
0.44
7.87
6.97
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/A
1.56
1.56
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/A
2.71
2.38
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
44.25
44.25

Institutional Ownership

CompanyInstitutional Ownership
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Geron Corporation stock logo
GERN
Geron
73.71%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
95.47%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
21.67%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
56.58 million6.20 millionOptionable
Geron Corporation stock logo
GERN
Geron
70636.92 million589.66 millionOptionable
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
2606.58 million5.67 millionNo Data
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
86205.25 million199.70 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.31 million107.71 millionOptionable

Recent News About These Companies

Futuristic laboratory, doctor or scientist holding glass tube, molecular and DNA structure, genetic research human biology and pharmaceutical technology, medical,science,development biological system — Photo
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
...
VKTX Viking Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$12.93 +0.68 (+5.55%)
As of 06/30/2025 04:00 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Geron stock logo

Geron NASDAQ:GERN

$1.41 -0.08 (-5.37%)
As of 06/30/2025 04:00 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Molecular Templates stock logo

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Spectrum Pharmaceuticals stock logo

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$26.50 -0.02 (-0.08%)
As of 06/30/2025 04:00 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.